Literature DB >> 25240470

Understanding primary aldosteronism: impact of next generation sequencing and expression profiling.

Silvia Monticone1, Tobias Else2, Paolo Mulatero3, Tracy A Williams3, William E Rainey4.   

Abstract

Primary aldosteronism (PA) encompasses a broad, heterogeneous group of disorders including both sporadic and familial forms (familial hyperaldosteronism type I, II and III). PA is the most common form of secondary hypertension and associated with a higher rate of cardiovascular complications, compared with essential hypertension. Despite significant progress in the diagnosis and management of PA, until recently the molecular mechanisms leading to inappropriate aldosterone production were largely unknown. The introduction of next-generation sequencing has had a profound impact on the field of human genetics and has given new insight in the molecular determinants that lead to both sporadic and familial forms of PA. Here we review the recent progress toward understanding of the genetic and molecular mechanisms leading to autonomous aldosterone production in PA.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ATP1A1; ATP2B3; CACNA1D; Exome sequencing; KCNJ5; Primary aldosteronism

Mesh:

Substances:

Year:  2014        PMID: 25240470      PMCID: PMC4285708          DOI: 10.1016/j.mce.2014.09.015

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  103 in total

1.  Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5.

Authors:  Ute I Scholl; Carol Nelson-Williams; Peng Yue; Roger Grekin; Robert J Wyatt; Michael J Dillon; Robert Couch; Lisa K Hammer; Frances L Harley; Anita Farhi; Wen-Hui Wang; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  Characterization of a novel somatic KCNJ5 mutation delI157 in an aldosterone-producing adenoma.

Authors:  Meena Murthy; Elena A B Azizan; Morris J Brown; Kevin M O'Shaughnessy
Journal:  J Hypertens       Date:  2012-09       Impact factor: 4.844

3.  Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas.

Authors:  F Fallo; V Pezzi; L Barzon; P Mulatero; F Veglio; N Sonino; J M Mathis
Journal:  Eur J Endocrinol       Date:  2002-12       Impact factor: 6.664

4.  Expression profiles for steroidogenic enzymes in adrenocortical disease.

Authors:  Mary H Bassett; Bobbie Mayhew; Khurram Rehman; Perrin C White; Franco Mantero; Giorgio Arnaldi; Paul M Stewart; Iwona Bujalska; William E Rainey
Journal:  J Clin Endocrinol Metab       Date:  2005-06-28       Impact factor: 5.958

5.  K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension.

Authors:  Murim Choi; Ute I Scholl; Peng Yue; Peyman Björklund; Bixiao Zhao; Carol Nelson-Williams; Weizhen Ji; Yoonsang Cho; Aniruddh Patel; Clara J Men; Elias Lolis; Max V Wisgerhof; David S Geller; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Wenhui Wang; Tobias Carling; Richard P Lifton
Journal:  Science       Date:  2011-02-11       Impact factor: 47.728

Review 6.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

Review 7.  Cushing's syndrome variants secondary to aberrant hormone receptors.

Authors:  André Lacroix; Valérie Baldacchino; Isabelle Bourdeau; Pavel Hamet; Johanne Tremblay
Journal:  Trends Endocrinol Metab       Date:  2004-10       Impact factor: 12.015

Review 8.  TASK1 and TASK3 potassium channels: determinants of aldosterone secretion and adrenocortical zonation.

Authors:  S Bandulik; D Penton; J Barhanin; R Warth
Journal:  Horm Metab Res       Date:  2010-01-04       Impact factor: 2.936

9.  The potassium channel, Kir3.4 participates in angiotensin II-stimulated aldosterone production by a human adrenocortical cell line.

Authors:  Kenji Oki; Maria W Plonczynski; Milay Luis Lam; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Endocrinology       Date:  2012-07-13       Impact factor: 4.736

10.  TASK channel deletion in mice causes primary hyperaldosteronism.

Authors:  Lucinda A Davies; Changlong Hu; Nick A Guagliardo; Neil Sen; Xiangdong Chen; Edmund M Talley; Robert M Carey; Douglas A Bayliss; Paula Q Barrett
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

View more
  21 in total

1.  Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series.

Authors:  Francesco Fallo; Isabella Castellano; Celso E Gomez-Sanchez; Yara Rhayem; Catia Pilon; Valentina Vicennati; Donatella Santini; Valeria Maffeis; Ambrogio Fassina; Paolo Mulatero; Felix Beuschlein; Martin Reincke
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

Review 2.  Personalized Therapy of Hypertension: the Past and the Future.

Authors:  Paolo Manunta; Mara Ferrandi; Daniele Cusi; Patrizia Ferrari; Jan Staessen; Giuseppe Bianchi
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 3.  Issues in the Diagnosis and Treatment of Primary Aldosteronism.

Authors:  Jacopo Burrello; Silvia Monticone; Fabrizio Buffolo; Martina Tetti; Giuseppe Giraudo; Domenica Schiavone; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-04-09

4.  Somatic mutations in adrenocortical carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism.

Authors:  Isobel C Mouat; Kei Omata; Andrew S McDaniel; Namita G Hattangady; Debnita Talapatra; Andi K Cani; Daniel H Hovelson; Scott A Tomlins; William E Rainey; Gary D Hammer; Thomas J Giordano; Tobias Else
Journal:  Endocr Relat Cancer       Date:  2019-02       Impact factor: 5.678

Review 5.  Familial hyperaldosteronism type III.

Authors:  S Monticone; M Tetti; J Burrello; F Buffolo; R De Giovanni; F Veglio; T A Williams; P Mulatero
Journal:  J Hum Hypertens       Date:  2017-04-27       Impact factor: 3.012

Review 6.  Development of adrenal cortex zonation.

Authors:  Yewei Xing; Antonio M Lerario; William Rainey; Gary D Hammer
Journal:  Endocrinol Metab Clin North Am       Date:  2015-06       Impact factor: 4.741

7.  A Novel Somatic Deletion Mutation of ATP2B3 in Aldosterone-Producing Adenoma.

Authors:  Masanori Murakami; Takanobu Yoshimoto; Isao Minami; Ryotaro Bouchi; Kyoichiro Tsuchiya; Koshi Hashimoto; Hajime Izumiyama; Yasuhisa Fujii; Takashi Endo; Takumi Akashi; Koshiro Nishimoto; Kuniaki Mukai; Kazunori Kihara; Yoshihiro Ogawa
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

Review 8.  Hyperaldosteronism: How to Discriminate Among Different Disease Forms?

Authors:  Valentina Crudo; Silvia Monticone; Jacopo Burrello; Fabrizio Buffolo; Martina Tetti; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-02

Review 9.  Aging and Adrenal Aldosterone Production.

Authors:  Kazutaka Nanba; Anand Vaidya; William E Rainey
Journal:  Hypertension       Date:  2017-12-11       Impact factor: 10.190

Review 10.  Hyperaldosteronism: Screening and Diagnostic Tests.

Authors:  Chiara Sabbadin; Francesco Fallo
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.